Alexion Pharma (ALXN) Tops Q2 EPS by 30c, Sales Beat; Raises Outlook

Alexion Pharma (NASDAQ: ALXN) reported Q2 EPS of $1.56, $0.30 better than the analyst estimate of $1.26. Revenue for the quarter came in at $912 million versus the consensus estimate of $845.53 million.

GUIDANCE:

Alexion Pharma sees FY2017 EPS of $5.40-$5.55, versus the consensus of $5.33.

• 2Q17 Total Revenues of $912 Million, a 21 Percent Increase Over 2Q16
• 2Q17 GAAP EPS of $0.73 Per Share, a 38 Percent Increase Year-Over-Year and Non-GAAPEPS of $1.56 Per Share, a 38 Percent Increase Year-Over-Year
• Positive CHMP Opinion Received for Soliris in Patients with Refractory gMG in the EU
• Completed Enrollment in the ALXN1210 Phase 3 PNH Study in Complement Inhibitor Treatment-Naive Patients
• Increasing 2017 Revenue Guidance to $3.450 to $3.525 Billion; Narrowing GAAP EPS Guidance to $2.82 to $3.12 Per Share and Increasing Non-GAAP EPS Guidance to $5.40 to $5.55 Per Share

For earnings history and earnings-related data on Alexion Pharma (ALXN) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• Aon names interim CFO as Edmund Reese exits the firm
• BWS Financial Downgrades Inter Parfums (IPAR) to Sell